基本信息
浏览量:104
职业迁徙
个人简介
RESEARCH INTERESTS:
The primary emphasis of the work in the Evans laboratory is to determine causes of treatment resistance in human cancer. The treatment resistance factor that is emphasized is hypoxia. The presence, level and distribution of hypoxia is measured using a 2-nitroimidazole agent, EF5, developed by Dr. Cameron Koch, also from the Department of Radiation Oncology, at PENN. EF5 can be used for in vitro or in vivo studies. The majority of studies in the Evans laboratory involve in vivo studies in animals or humans. Given intravenously, this agent is reduced and bound in hypoxic cells. The adducts thus formed are recognized by a specific fluorescent monoclonal antibody. Tumor tissue or cells are studied either using immunohistochemistry or flow cytometry. This fluorescence can be measured and converted into tissue pO2 based upon previously published in vitro studies. We have performed studies using EF5 in animal models of cancer and, since 1998 have been performing clinical trials to evaluate the presence and level of hypoxia in various human cancers. We are currently funded by the NIH to perform studies in human brain tumors, head and neck cancers, sarcomas, cervix, and intraperitoneal cancers. We have shown that hypoxia, as measured by EF5 binding correlates to the level of tumor aggression in glial brain tumors, soft tissue sarcomas and head/neck squamous cell cancers. We have recently been able to produce [F-18]-EF5, which can be analyzed with positron emission tomography, PET imaging. Grants to study EF5 binding, with both immunohistochemical and PET endpoints in patients with brain tumors and head and neck cancer have been funded by the NIH.
The primary emphasis of the work in the Evans laboratory is to determine causes of treatment resistance in human cancer. The treatment resistance factor that is emphasized is hypoxia. The presence, level and distribution of hypoxia is measured using a 2-nitroimidazole agent, EF5, developed by Dr. Cameron Koch, also from the Department of Radiation Oncology, at PENN. EF5 can be used for in vitro or in vivo studies. The majority of studies in the Evans laboratory involve in vivo studies in animals or humans. Given intravenously, this agent is reduced and bound in hypoxic cells. The adducts thus formed are recognized by a specific fluorescent monoclonal antibody. Tumor tissue or cells are studied either using immunohistochemistry or flow cytometry. This fluorescence can be measured and converted into tissue pO2 based upon previously published in vitro studies. We have performed studies using EF5 in animal models of cancer and, since 1998 have been performing clinical trials to evaluate the presence and level of hypoxia in various human cancers. We are currently funded by the NIH to perform studies in human brain tumors, head and neck cancers, sarcomas, cervix, and intraperitoneal cancers. We have shown that hypoxia, as measured by EF5 binding correlates to the level of tumor aggression in glial brain tumors, soft tissue sarcomas and head/neck squamous cell cancers. We have recently been able to produce [F-18]-EF5, which can be analyzed with positron emission tomography, PET imaging. Grants to study EF5 binding, with both immunohistochemical and PET endpoints in patients with brain tumors and head and neck cancer have been funded by the NIH.
研究兴趣
论文共 59 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Gwendolyn Cramer,Robert Lewis, Ashley Gymarty,Sarah Hagan, Michela Mickler,Sydney Evans,Salman R Punekar, Lee Shuman,Charles B Simone,Stephen M Hahn,Theresa M Busch, Douglass Fraker,
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn